Genomic Health to present prostate cancer studies at ASCO Genitourinary Cancer Symposium

January 21, 2016

Additionally, since prior studies from other groups have had mixed results, researchers conducted a separate analysis on the RNA to determine if an association exists between prostate cancer DNA alterations that have been recently discovered (gene rearrangements called TMPRSS2-ERG fusions) and adverse clinical outcomes.  Results from this study indicated that there is no association of expression of TMPRSS2-ERG fusions or ERG expression with aggressiveness of prostate cancer after radical prostatectomy.  Specifically, researchers did not find an association of TMPRSS2-ERG gene rearrangements or ERG expression with clinical recurrence, PSA recurrence, or PCA-specific survival in either primary or highest Gleason pattern tumor samples.  The study, "Use of TMPRSS2-ERG gene rearrangement and quantitative ERG expression to predict clinical recurrence after radical prostatectomy" (Klein et al, Abstract #36), will be presented in a poster session on Thursday, February 17.  

Quantitative Gene Expression Using RT-PCR Adds Prognostic Information Beyond Clinical and Pathological Criteria

A separate analysis utilizing the same RNA as the studies presented at ASCO-GU will be presented at the USCAP 2011 meeting in San Antonio, Texas and suggests that prostate cancer gene expression adds prognostic information beyond clinical and pathological criteria such as prostate-specific antigen (PSA), The American Urological Association (AUA) criteria and Cancer of the Prostate Risk Assessment (CAPRA) Score.  The analysis showed that many genes were significantly (unadj. p<0.05) associated with clinical recurrence, PSA recurrence, and PCSS (295, 235, and 203 genes respectively).  Additionally, many genes remained significantly associated with each of the outcomes in multivariate analyses adjusting for pathologic T-stage, tumor specimen Gleason pattern (GP), Gleason score (GS), AUA group and CAPRA score.  For the strongest 20 genes, the magnitude of association was diminished by less than 20 percent after adjustment for stage, GP, AUA, and CAPRA, and less than 50 percent after adjustment for GS.  The study, "Prostate Cancer Gene Expression Adds Prognostic Information beyond Clinical and Pathological Criteria Such as Stage, Gleason Score, PSA, AUA Criteria, and CAPRA Score " (Falzarano et al, Abstract #803), will be presented in an oral session on Monday, February 28 at 1:45 p.m. CT.

SOURCE Genomic Health, Inc.